175 related articles for article (PubMed ID: 30713784)
1. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate.
Border EC; Sanderson JP; Weissensteiner T; Gerry AB; Pumphrey NJ
Oncoimmunology; 2019; 8(2):e1532759. PubMed ID: 30713784
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP; Crowley DJ; Wiedermann GE; Quinn LL; Crossland KL; Tunbridge HM; Cornforth TV; Barnes CS; Ahmed T; Howe K; Saini M; Abbott RJ; Anderson VE; Tavano B; Maroto M; Gerry AB
Oncoimmunology; 2020; 9(1):1682381. PubMed ID: 32002290
[TBL] [Abstract][Full Text] [Related]
4. Tuning T cell receptor sensitivity through catch bond engineering.
Zhao X; Kolawole EM; Chan W; Feng Y; Yang X; Gee MH; Jude KM; Sibener LV; Fordyce PM; Germain RN; Evavold BD; Garcia KC
Science; 2022 Apr; 376(6589):eabl5282. PubMed ID: 35389803
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
6. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
7. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.
Obenaus M; Leitão C; Leisegang M; Chen X; Gavvovidis I; van der Bruggen P; Uckert W; Schendel DJ; Blankenstein T
Nat Biotechnol; 2015 Apr; 33(4):402-7. PubMed ID: 25774714
[TBL] [Abstract][Full Text] [Related]
8. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
9. TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
Front Immunol; 2019; 10():2501. PubMed ID: 31695703
[TBL] [Abstract][Full Text] [Related]
10. High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
Vazquez-Lombardi R; Jung JS; Schlatter FS; Mei A; Mantuano NR; Bieberich F; Hong KL; Kucharczyk J; Kapetanovic E; Aznauryan E; Weber CR; Zippelius A; Läubli H; Reddy ST
Immunity; 2022 Oct; 55(10):1953-1966.e10. PubMed ID: 36174557
[TBL] [Abstract][Full Text] [Related]
11. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
12. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
13. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P; Kranz DM
Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
[TBL] [Abstract][Full Text] [Related]
14. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
Stone JD; Harris DT; Kranz DM
Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
[TBL] [Abstract][Full Text] [Related]
15. T-cell Receptors for Clinical Therapy:
Kunert A; Obenaus M; Lamers CHJ; Blankenstein T; Debets R
Clin Cancer Res; 2017 Oct; 23(20):6012-6020. PubMed ID: 28645940
[TBL] [Abstract][Full Text] [Related]
16. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
[TBL] [Abstract][Full Text] [Related]
19. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
20. T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation.
Bentzen AK; Hadrup SR
Immunooncol Technol; 2019 Sep; 2():1-10. PubMed ID: 35036898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
